Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. - Wikidata - wikimedia - TriplyDB

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.

http://www.wikidata.org/entity/Q40133703

about

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab Current targeted therapies in the treatment of advanced colorectal cancer: a review Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors Molecularly targeted drugs for metastatic colorectal cancer EGFR/HER-targeted therapeutics in ovarian cancer Beyond the Barriers of Light Penetration: Strategies, Perspectives and Possibilities for Photodynamic Therapy Optical metabolic imaging of treatment response in human head and neck squamous cell carcinoma A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death Enhanced Therapeutic Epidermal Growth Factor Receptor (EGFR) Antibody Delivery via Pulsed Ultrasound with Targeting Microbubbles for Glioma Treatment Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines.Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.Immunotherapy in head and neck cancer: aiming at EXTREME precision.Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers.Understanding resistance to EGFR inhibitors-impact on future treatment strategies Experimental approaches for the treatment of malignant gliomas.Targeting the EGFR signaling pathway in cancer therapy.Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer.Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells Serial Measurements of Apoptotic Cell Numbers Provide Better Acceptance Criterion for PBMC Quality than a Single Measurement Prior to the T Cell Assay.Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.A wortmannin-cetuximab as a double drug KRAS mutant colorectal tumors: past and present Cancer immunotherapy: Progress and challenges in the clinical setting.Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.Interleukin-1 beta transactivates epidermal growth factor receptor via the CXCL1-CXCR2 axis in oral cancer.miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells.Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer.Immunological off-target effects of standard treatments in gastrointestinal cancers Targeting the EGF receptor ectodomain in the context of cancer.ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.Optimal treatment for recurrent/metastatic head and neck cancer.Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors.Monoclonal antibodies in lung cancer.Role of targeted agents in metastatic colorectal cancer.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era.Exceptional response to cetuximab monotherapy in a patient with metastatic oropharyngeal squamous cell carcinoma: a molecular insight.

P2860

Q21245712-E178D506-9D3D-422C-8C29-46CC91A13103 Q24600031-7B58DBE3-2928-4173-84B8-425212525708 Q26740067-93C72849-2FAA-4C39-85BB-B4A417A4870E Q26750719-90B9D5F6-5DFD-4BA6-8540-37D2B5B0D582 Q26828735-509EE807-35DE-49F9-9D51-7D77B01886BC Q26863231-B52CCBD4-10E4-4D3B-A506-AD47A9EA2B4C Q28079955-A29DB39F-D37F-48BF-A8CC-AE6A7E041269 Q28540413-628F7643-BF13-4145-89DE-34DD5359ACDD Q28740749-134AC1B6-5900-452B-B179-A0B23106D730 Q30412519-C5A30B0A-AC3B-4419-A77C-AA7C3B95E9C7 Q33358967-A6FFA4E1-CE85-44DB-9863-2131466BFA8D Q33398899-315FBD50-2A28-4FD8-8AC3-89E1FE70CE25 Q33756244-F0D51804-CA67-4BAB-B06B-B76AAA7859B7 Q34052270-072B2255-97D0-4AE7-8266-C58BD031C871 Q34088424-99756C6A-4E5C-44FC-B5AA-ED7715C4F2E7 Q34127138-848894AB-2E39-44A8-A37F-7C1428665BC8 Q34246558-9D213A52-9C21-4BAA-AD57-2A0EE0BCE18A Q34321100-B3A5EA05-F598-4BEE-A6E0-48DE2378343D Q35001415-25361BEE-DE04-437D-B47D-6AAC5BAD2313 Q35068059-9916C9E4-4460-4A89-985E-F80C757EFB57 Q35153765-A0EADDFB-DEE7-4110-80A0-79D846453119 Q35237387-1B6D0271-B0B5-4DFE-B902-9266AFEA4A2C Q36019729-744F6DD1-C2D7-494F-A108-B2E1E501A3F8 Q36067672-F0C50A2A-FC7E-4CBF-8985-35E637A1F842 Q36100844-5D37FAC6-FB3E-4853-990B-729140D5F322 Q36184314-A4C583BF-5E78-432F-9051-40E90FF00AED Q36624335-FA4DAD3D-D68F-4EC5-AFE4-0EA46B1E1793 Q36629444-C44F4AC0-E688-43CD-A879-F5EB5B6F233A Q36962611-DA5B8F45-C815-4BDA-B052-E93C757C191D Q37118923-FB4ED047-C5E6-4BB9-B7C4-B1C4E45AB9BD Q37404086-36798F1A-4E8C-4447-B015-2DD7FB67C970 Q37600910-B88C78ED-5A0A-45BA-9D5D-4A6A0F95252D Q37725589-349A5DAE-DEBD-4602-880D-1326792BB35C Q37799934-E4D5C110-A38F-4CF6-97B7-49E43C5B9801 Q37887819-B19429A6-1557-4039-8EF4-8225030FECA2 Q38067454-327FB25E-25CB-4E55-9790-82579229D748 Q38104294-32F68800-F83E-4062-8A1D-1DF9BE3658CC Q38214511-9AE94590-8442-4A46-9E12-0BBC58E69DC3 Q38221293-C9D15F42-CE38-41DE-9925-31BBFE6EECF2 Q38503146-3167F918-B3DA-4EC9-821C-AF95633D7A71

P2860

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.

http://www.wikidata.org/entity/Q40133703

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Antibody-dependent cellular cy ...... dermal growth factor receptor.

@en

type

label

Antibody-dependent cellular cy ...... dermal growth factor receptor.

@en

prefLabel

Antibody-dependent cellular cy ...... dermal growth factor receptor.

@en

P1433

Q40133703-73D1ABDE-6FEF-43EC-A1FD-E4444DAA93BF

P1476

Q40133703-0F9D59B7-70EB-4CF4-89B3-B6E4FDBEA0D5

P2093

Q40133703-22A7AEE1-0E3B-4B2B-9885-1D25189335F0

Q40133703-6D1A094F-091B-49DE-9CFA-E265A5EE9CBA

Q40133703-87E3A203-1DAC-46BC-A762-126CA53BA02C

Q40133703-C46AF1B4-079B-469F-9B1C-651DF1C8C208

Q40133703-D7598D10-65D5-4B15-A258-7B71504EC5DD

Q40133703-DD99D542-2392-457C-B430-77235E3DC7EE

P2860

Q40133703-00A2D5A1-E01D-4BB4-9A34-DB47AA0BAA43

Q40133703-00AD8909-C5B1-41E8-BD53-DF01A92717FA

Q40133703-123BAF49-1809-4D03-8195-58BA7819B4C9

Q40133703-2083A475-EFF2-4F05-BB6B-16B6BC35F974

Q40133703-2B2DCD30-4B38-45E7-A897-D24E970CD09B

Q40133703-493E64AE-3939-4A69-B8D6-B7AC4299C084

Q40133703-4CCD72A7-91EF-4C6A-AEE7-694587197FCB

Q40133703-59EEAA22-5D25-4191-86AC-B09F84439E68

Q40133703-8A49B449-CB4A-48FE-8677-343466608ADB

Q40133703-AC179056-46E3-4C5E-A1D5-E1FBAC2E47E7

P304

Q40133703-457A00B2-C009-451F-9DFB-83F45F08886F

P31

Q40133703-B6F58438-B902-4646-8A58-0B546AC0AFF0

P356

Q40133703-B24866B8-A883-4061-8F5E-50636E2F4D87

P433

Q40133703-D8BBF8F1-6CB8-4730-B936-0AED22DD9202

P478

Q40133703-8887ED2B-5A93-40E6-8CB3-FAE107DDEB8A

P577

Q40133703-1428688E-341D-414A-A785-CE7A0F300A89

P5875

Q40133703-6ECE271F-4AFA-487D-BA90-189BE6361930

P698

Q40133703-8C946341-2D99-475D-BD13-CA14058D94CF

P921

Q40133703-30D5EFCE-F786-49EC-BD32-84934C709042

Q40133703-56BA91B1-41C0-4D37-AA78-162A05123308

Q40133703-B09606BC-5675-4D3A-B46D-216750E63176

P356

J.1349-7006.2007.00510.X

P1433

P1476

Antibody-dependent cellular cy ...... dermal growth factor receptor.

@en

P2093

Hideharu Kimura

http://www.w3.org/2001/XMLSchema#string

Kazuko Sakai

http://www.w3.org/2001/XMLSchema#string

Kazuto Nishio

http://www.w3.org/2001/XMLSchema#string

Tatsu Shimoyama

http://www.w3.org/2001/XMLSchema#string

Tokuzo Arao

http://www.w3.org/2001/XMLSchema#string

Tomohide Tamura

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Epidermal growth factor-related peptides and their receptors in human malignancies

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.

The ErbB receptor family: a therapeutic target for cancer.

Monoclonal antibodies targeting the epidermal growth factor receptor.

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.

Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.

P304

1275-1280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1349-7006.2007.00510.X

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2007-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6334271

http://www.w3.org/2001/XMLSchema#string

P698

17498200

http://www.w3.org/2001/XMLSchema#string

P921